Repligen Stock Price, News & Analysis

Repligen Corporation (NASDAQ:RGEN) will release its third quarter 2021 financial results on October 28, 2021, prior to market open. A conference call will follow at 8:30 a.m. EDT to discuss business updates and results for the three- and nine-month periods ending September 30, 2021. Interested parties can access the call by dialing specific numbers based on their location. Repligen, a life sciences company, focuses on innovative bioprocessing technologies for biopharmaceutical manufacturers globally. More details can be found on their website.

Repligen Corporation (NASDAQ:RGEN) has entered into a definitive agreement to acquire Avitide Inc. for approximately $150 million. The deal includes $75 million in cash and $75 million in Repligen common stock, alongside performance-based earnouts over three years. This acquisition aims to enhance Repligen’s Proteins business, particularly in affinity ligand solutions for gene therapy, with Avitide expected to contribute about $10 million in revenue in 2022 and positively impact adjusted earnings per share in 2023.

Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH announced the successful development of a novel protein A ligand called NGL-Impact A Hi pH. This innovative ligand addresses critical challenges in purifying pH sensitive antibodies and Fc-fusion proteins, notably reducing antibody aggregation during purification. Customer evaluations showcased a two-fold decrease in aggregate formation while maintaining high dynamic binding capacity. The ligand is set for commercialization via a new resin later this year, potentially offering significant cost and time savings for developers in the biopharmaceutical industry.

Repligen Corporation (NASDAQ:RGEN) reported Q2 2021 revenue of $163.0 million, achieving an 86% year-over-year growth and 69% organic growth. The company raised its revenue guidance for 2021 to $625-$645 million from previous estimates of $565-$590 million. The acquisition of Polymem S.A. further enhances Repligen's capabilities. Key financial metrics include a GAAP EPS of $0.64 and adjusted EPS of $0.79 for the quarter. The company anticipates a gross margin of 59%-60% for the year, reflecting ongoing strong performance.

Repligen Corporation (NASDAQ:RGEN) will report its Q2 2021 financial results on July 27, 2021. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. EDT to discuss financial results for the three- and six-month periods ending June 30, 2021. Domestic callers can dial (844) 274-3999, while international callers can use (412) 317-5607. The call will also be available via a webcast on the company’s Investor Relations webpage, with archived access provided as well.

Repligen Corporation (NASDAQ:RGEN) announced its acquisition of Polymem S.A., a French specialist in hollow fiber membranes, on June 22, 2021. This acquisition enhances Repligen's production capabilities and R&D expertise, positioning it to meet growing demand in both industrial and bioprocessing markets. The deal is expected to close in Repligen's third fiscal quarter of 2021, utilizing cash reserves of approximately $711 million as of March 31, 2021. Polymem's leadership will remain in place post-acquisition, aiming to expand market reach and growth opportunities.

Repligen Corporation (NASDAQ:RGEN) has announced its participation in two virtual investor conferences. CEO Tony J. Hunt will join the William Blair 41^st Annual Growth Stock Conference on June 1 at 1:40 p.m. EST and the Jefferies Virtual Healthcare Conference on June 3 at 2:30 p.m. EST. These discussions will be available via live webcast and can be replayed afterward. Repligen focuses on developing innovative bioprocessing technologies for biopharmaceutical manufacturers globally.

Repligen Corporation (NASDAQ:RGEN) reported a remarkable first-quarter revenue of $142.8 million, reflecting an 88% year-over-year increase and 69% organic growth. Key growth drivers included COVID-related demand contributing 25% of total revenue, alongside a 31% increase in its non-COVID base business. The company also revised its 2021 financial outlook, expecting total revenue between $565-$590 million, significantly up from previous guidance. GAAP EPS rose to $0.52 from $0.18 year-on-year. Adjusted EPS reached $0.68, compared to $0.32 in Q1 2020.

Repligen Corporation (NASDAQ:RGEN) will report its Q1 2021 financial results on May 4, 2021, with a press release issued before market opening. A conference call will be held at 8:30 a.m. EDT to discuss the results for the three-month period ending March 31, 2021. Callers can join via toll-free numbers for domestic and international participants, with no passcode required. The event will also be available for replay. As a leading life sciences company, Repligen specializes in innovative bioprocessing technologies aimed at enhancing biopharmaceutical manufacturing efficiency.